GlassScriptPhysician profile
Michele Pierce
NPI 1255668968
$1,315.41
in general payments reported to CMS, 2019-2025
18 companies · $707 in 2025
The $707 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.18 · 2023: $58.13 · 2024: $531 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279 · Education: $17.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.65 |
| Education | $17.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185.60 | 2023-2025 | |
| Madrigal Pharmaceuticals | $154.07 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $148.14 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.95 | 2024-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $118.25 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $112.26 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $97.58 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Ardelyx, INC. | $80.12 | 2024-2025 | Ibsrela |
| Vivus LLC | $42.91 | 2025 | Qsymia, Pancreaze |
| Intercept Pharmaceuticals, INC. | $42.85 | 2024 | |
| Celgene Corporation | $42.59 | 2024 | Zeposia |
| Pfizer INC. | $35.04 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $23.29 | 2024 | |
| Novo Nordisk INC | $21.53 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $19.18 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.16 | 2025 | Relistor |
| Celltrion USA INC. | $17.58 | 2024 | Zymfentra |
| Aimmune Therapeutics, INC. | $14.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.